The company is significantly expanding capacity at its sterile site in Latina, Italy, investing more than €20 million over the past 24 months to offer customers a high-performance site with state-of-the-art filling technology for sterile dosage forms, namely vials and prefilled syringes (PFS). This new manufacturing area has been approved by the Italian authorities.
Follow-on investments of approximately €15 million are currently underway to further expand the offering and increase capacity for prefilled syringes (PFS).
In a statement, Aenova said the move is in response to market demand for PFS and increased customer requirements for this fast-growing sterile dosage form. Aenova is also positioning itself as a service-oriented end-to-end provider in this area.
As part of a comprehensive reorganization of Aenova’s other sterile sites, the Haupt Pharma Wolfratshausen GmbH site will be closed in 2023 and the sterile manufacturing sub-segment at the Gronau site, Haupt Pharma Wülfing GmbH, will be discontinued. Customer projects are expected be transferred or completed according to plan. The Gronau site will focus on the successful solid business with capacity expansions underway.
“Our restructuring and focus on our Latina sterile site, is targeting a growth market,” said Jan Kengelbach, CEO of the Aenova Group. “This pays off for the entire Aenova strategy. It puts us in an excellent position for the future.”